MCTA vs FCFS Stock Comparison

Charming Medical and FirstCash Holdings Prices as of Oct 22, 2026 Peers: Industry group
MCTA Charming Medical Ltd
$29.35 0.0% 1M +373.4% 1Y
Market cap
$445.47M
P/E
–
Revenue (TTM)
—
Div. yield
–
Personal Services Consumer Discretionary
1 win
FCFS FirstCash Holdings, Inc.
$172.75 -20.2% 1M +11.6% 1Y
Market cap
$7.67B
P/E
19.8x
Revenue (TTM)
$4.12B
Div. yield
–
Consumer Lending Financial Services
2 wins

Head to Head

3 decided of 12

FirstCash Holdings leads on 2 of the 12 questions below (FirstCash Holdings 2, Charming Medical 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionMCTAFCFSLeader
Larger companyMarket capitalisation $445.47M $7.67B FCFS
Cheaper on earningsLower P/E, profitable companies only -20,929x 19.8x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 14.8x –
Faster revenue growthRevenue growth, trailing twelve months — +21.6% –
More profitableNet margin, trailing twelve months — 9.4% –
Better return on capitalReturn on invested capital — 8.4% –
Less leveragedLower net debt / EBITDA — 3.3x –
Higher dividend yieldTrailing dividend yield — 0.00% –
Better 1-year returnPrice return, last 12 months +373.4% +11.6% MCTA
Better 5-year returnAnnualised price return, 5 years — +13.7%/yr –
Less volatileAnnualised volatility, 1 year 74.7% 36.1% FCFS
Higher overall scoreMean of the five percentile scores vs peers — 59/100 –

Percentile Scorecard

MCTAFCFS

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisMCTAFCFS
Valuation 0 #33 of 33 47 #91 of 170
Growth – 76 #41 of 165
Profitability – 77 #36 of 155
Financial Health 84 #7 of 39 67 #55 of 163
Shareholder Returns – 28 #99 of 137
Overall – 59
  • MCTA ranked among 39 companies in Consumer Services
  • FCFS ranked among 175 companies in Lending and Credit

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodMCTAFCFSSPY
1 month 0.0%-20.2% -1.0%
3 months 0.0%-11.4% +2.9%
6 months 0.0%-21.1% +6.4%
Year to date 0.0%+8.4% +11.4%
1 year +373.4%+11.6% +13.1%
3 years —+69.7% +79.4%
3 years, per year —+19.3% +21.5%
5 years —+89.9% +67.7%
5 years, per year —+13.7% +10.9%
10 years —+268.7% +255.2%
10 years, per year —+13.9% +13.5%

Risk

MeasureMCTAFCFSSPY
Volatility, 1Y 74.7%36.1% 12.7%
Downside volatility, 1Y —40.4% 12.7%
Beta vs S&P 500, 1Y 0.300.65 1.00
Return / volatility, 1Y 5.000.32 1.03
Max drawdown, 5Y -25.6%-36.2% -25.4%
From 52-week high 0.0%-26.9% -2.5%
52-week high $29.35$236.43 $779.14
52-week low $6.20$148.05 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleMCTAFCFS
P/E now vs peer median -20,929xmedian 16.9x 19.5xmedian 11.0x
P/S now vs peer median 92.7xmedian 1.3x 1.8xmedian 2.6x
EV/EBITDA now vs peer median —median 9.4x 14.7xmedian 13.1x
P/FCF now vs peer median -286.4xmedian 14.5x 14.1xmedian 6.9x
P/B now vs peer median 86.0xmedian 2.0x 3.2xmedian 0.7x
PEG now vs peer median —median 0.33 0.97median 0.31

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsMCTAFCFS
Revenue – $4.12B
Gross profit – $2.08B
Operating income – $527.40M
Net income – $388.15M
Free cash flow – $531.91M
EPS (diluted) – $8.81
Cash & equivalents $4.70M $172.30M
Total debt – $2.35B
Shares (diluted) 16.15M 44.04M
Enterprise value $439.45M $7.12B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricMCTAFCFS
P/E -20,929x 19.5x
P/FCF -286.4x 14.1x
P/Operating cash flow – 11.1x
P/S 92.7x 1.8x
P/B 86.0x 3.2x
P/Tangible book 86.0x 3.5x
EV/EBITDA – 14.7x
EV/EBIT – 18.3x
EV/Revenue – 2.3x
EV/FCF – 18.2x
EV/Operating cash flow – 14.4x
PEG (3Y EPS CAGR) – 0.97

Growth

14 metrics
MetricMCTAFCFS
Revenue growth (1Y) – 21.6%
Revenue CAGR (3Y) – 12.0%
Gross profit growth (1Y) – 24.1%
Gross profit CAGR (3Y) – 14.8%
Operating income growth (1Y) – 36.3%
Operating income CAGR (3Y) – 20.6%
Net income growth (1Y) – 33.0%
Net income CAGR (3Y) – 18.7%
EPS growth (1Y) – 34.6%
EPS CAGR (3Y) – 20.2%
Operating cash flow growth (1Y) – 21.3%
Operating cash flow CAGR (3Y) – 14.5%
Free cash flow growth (1Y) – 29.7%
Free cash flow CAGR (3Y) – 15.5%

Profitability

14 metrics
MetricMCTAFCFS
Gross margin – 50.5%
EBITDA margin – 15.9%
Operating margin – 12.8%
Pretax margin – 12.8%
Net margin – 9.4%
FCF margin – 12.9%
Operating cash flow margin – 16.3%
Return on equity – 16.8%
Return on assets – 7.2%
Return on invested capital – 8.4%
Return on capital employed – 10.5%
Asset turnover – 0.8x
Cash conversion (OCF / net income) – 1.7x
Stock comp / revenue – 0.5%

Financial Health

11 metrics
MetricMCTAFCFS
Debt / assets 1.9% 42.8%
Debt / equity 0.0x 1.0x
Net debt / EBITDA – 3.3x
Debt / FCF – 4.4x
Liabilities / assets 47.5% 57.7%
Equity / assets 52.5% 42.3%
Interest coverage – 3.8x
Current ratio 1.9x 4.9x
Quick ratio 1.4x 0.4x
Cash ratio 1.4x 0.4x
Altman Z-score – 3.31

Shareholder Returns

7 metrics
MetricMCTAFCFS
Dividend yield – 1.0%
Net buyback yield – 2.3%
Shareholder yield – 3.3%
Payout ratio (earnings) – –
Payout ratio (FCF) – –
Dividend growth (1Y) – –
Dividend CAGR (3Y) – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusMCTAFCFS
Forward P/E – 14.8xFY2026
EPS, next fiscal year – $11.64FY2026
EPS growth, next FY – +32.9%FY2026
EPS growth, the year after – +8.4%
Revenue, next fiscal year – $4.27BFY2026
Revenue growth, next FY – +16.8%FY2026
Revenue growth, the year after – +3.9%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersMCTAFCFS
Held by institutions – 97.2%
Institutions holding – 500
Change in shares held, QoQ – +2.9%
Institutions buying – 253
Institutions selling – 166
Buyers to sellers – 1.52

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

MCTAFCFS
MCTA 1.00 0.08
FCFS 0.08 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, MCTA and FCFS?

FirstCash Holdings (FCFS) is the largest by market capitalisation: Charming Medical (MCTA) $445.47M, FirstCash Holdings (FCFS) $7.67B.

Which stock has performed better?

Over the past year Charming Medical (MCTA) returned the most: Charming Medical (MCTA) +373.4%, FirstCash Holdings (FCFS) +11.6%. Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, FirstCash Holdings (FCFS) has been the steadiest (Charming Medical (MCTA) 74.7%, FirstCash Holdings (FCFS) 36.1%). Volatility measures how widely the price swings, not the risk of the business.

Do MCTA and FCFS move together?

Their daily returns over the past year have a correlation of 0.08, a weak relationship. Holding both diversifies more than two closely linked stocks would.

Which is the better stock, MCTA and FCFS?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, FirstCash Holdings (FCFS) leads on 2. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.